Critical Comparison: BioLargo (BLGO) versus Its Rivals

BioLargo (NASDAQ:BLGO) is one of 33 publicly-traded companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its peers? We will compare BioLargo to related companies based on the strength of its valuation, profitability, risk, dividends, analyst recommendations, institutional ownership and earnings.

Risk and Volatility

BioLargo has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.81, meaning that their average stock price is 81% more volatile than the S&P 500.

Profitability

This table compares BioLargo and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-591.84%	5.15%	-0.65%

Earnings & Valuation

This table compares BioLargo and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.12
BioLargo Competitors	$6.84 billion	$211.64 million	67.91

BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and price targets for BioLargo and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1250	1568	44	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 13.47%. Given BioLargo’s peers higher possible upside, analysts plainly believe BioLargo has less favorable growth aspects than its peers.

Insider & Institutional Ownership

0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.3% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 10.3% of shares of all “Chemicals & allied products” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BioLargo peers beat BioLargo on 7 of the 9 factors compared.

About BioLargo

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.